Vibrosense Dynamics AB (publ) announced that the company's patent application "CIPN Prediction", to assess the risk of developing permanent nerve damage when treating cancer with chemotherapy, is published by the European Patent Office EPO on January 3, 2024. With the publication of the application, the company has a "provisional protection" for patent infringement. The patent application "CIPN prediction" describes a method and a Biomarker to assess the risk, in different treatment options, to develop permanent nerve damage after completion of treatment.

With the patent as a basis, the company's preliminary algorithm can provide doctors with a prognostic tool when choosing different chemotherapy treatments.